AvengeBio develops cell-generated immunotherapies aimed at eradicating solid tumors by harnessing the body's immune response. The company targets the challenge of treatment-resistant cancers, providing a potential solution for patients with limited options.
Funding
$45M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many solid tumors develop resistance to existing cancer therapies, leaving patients with limited or no effective treatment options. These resistant tumors often evade the body's natural immune response, hindering the ability to fight the cancer.
Solution
AvengeBio was developing cell-generated immunotherapies designed to stimulate the body's immune system to target and eradicate solid tumors. Their approach aimed to overcome treatment resistance by enhancing the immune system's ability to recognize and destroy cancer cells. The company sought to provide a potential therapeutic option for patients with advanced solid tumors who have exhausted other treatment avenues.
Target Audience
The intended target audience was patients with solid tumors that are resistant to conventional cancer treatments.
Features
- Cell-based immunotherapy approach
- Designed to stimulate a targeted immune response against solid tumors
- Focus on overcoming treatment resistance in cancer